% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Apr 21, 2011 4:16 PM Flag

    t.beta,kidney dialysis abs.

    New abstract.This one in Japan.

    <<<On-line solid-phase extraction LC-MS/MS for the determination of Ac-SDKP peptide in human plasma from hemodialysis patients.
    Inoue K, Ikemura A, Tsuruta Y, Tsutsumiuchi K, Hino T, Oka H.

    Department of Physical and Analytical Chemistry, School of Pharmacy, Kinjo Gakuin University, 2-1723 Omori, Moriyama-ku, Nagoya, Aichi, 463-8521, Japan.

    We developed a high-throughput method based on on-line solid-phase extraction liquid chromatography tandem mass spectrometry (SPE-LC-MS/MS) to determine N-terminal thymosin-β fragment peptide (N-acetyl-seryl-aspartyl-lysyl-proline, Ac-SDKP) in human plasma samples. Quantification of Ac-SDKP was performed using direct injection for on-line SPE based on C(18) , reversed-phase LC separation and stable isotope dilution electrospray ionization-MS/MS in multiple reaction-monitoring (MRM) mode. The Ac-SDKP-(13) C(6) , (15) N(2) (m/z 496 → 137) was synthesized for the internal standard. The MRM ion for Ac-SDKP was m/z 488 → 129 (quantitative ion)/226. The limit of detection and lower limit of quantitation were 0.05 and 0.1 ng/mL in standard solution, respectively. Recovery values were 98.3-100.4% with inter-day (relative standard deviation, RSD, 0.4-14.1%) and intra-day (RSD, 0.8-19.7%) assays. This method was applied to the measurement of Ac-SDKP levels in plasma from hemodialyzed subjects. Concentrations were 0.59 ± 0.23 ng/mL (pre-hemodialyzed subjects, n = 9) and 0.44 ± 0.19 ng/mL (post-hemodialyzed subjects, n = 9). All plasma Ac-SDKP levels were decreased by dialysis. Thus, plasma Ac-SDKP was decreased through dialysis in chronic kidney disease. The findings in this study will be useful for the treatment of anemia in chronic kidney disease with dialysis.>>>

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • what are these reasearchers saying? They measured the Thymosin Beta fragments in HUMAN blood samples of patients with kidney didease that are undergoing a dialysis machine. what it seems these researchers were doing was measuring the Thymosin beta fragments, IN HUMANS....(not a mouse test)..both BEFORE they hooked up to the dialysis machine..and AFTER.

      The way I read it is..that they say that the Thymosin Beta fragments are lower....after you finish the dialysis, than before. And somehow they link the Thymopsin beta anemia in patients.

      I believe some of the biggest drugs a tiny , tiny biotech - called AMGEN - has are ones for anemia.Is that right?? If simply adding some TB 4 into the dialysis machine at some low concentrations.....helps treat anemia??? It's a big thing.

      Don't expect Finklestin to ever do anything with it though. Only thing he is competant at is checking his Bank salary deposit slips. His total comp weekly (including bene's) is about (gross) $5500 a week.

      Boy are we getting screwed. Does ANYONE know what ANY other tiny biotech would get (bounce wise) on research like this???? It's HUMANS.....not mice.

      • 1 Reply to snogreen
      • AMGEN.....(amgn)...has a market cap about $50 billion. Net of debt they have about $4 (plus) billion in cash. Their net income is almpst $5 billion annually. Sales are over $15 billion. On what??? - This is from yesterday!

        <<<Amgen Inc., the world’s largest biotechnology company, said first-quarter profit fell 3.6 percent as sales of the company’s anemia drugs declined and marketing expenses increased because of a new bone treatment.

        Net income dropped to $1.13 billion, or $1.20 a share, from $1.17 billion, or $1.18, a year earlier, the Thousand Oaks, California-based company said today in a statement. Earnings excluding one-time items beat by 5 cents the $1.29 average estimate of 22 analysts surveyed by Bloomberg.

        Combined sales of the company’s anemia medications Aranesp and Epogen, used by patients with kidney disease, fell 11 percent on declining use due to tighter rules on reimbursement from Medicare.>>

        See the key??? AMGN's two biggest drugs are :......."anemia medications Aranesp and Epogen, used by patients with kidney disease."

        AMGN is a $50 BILLION company that was built on anemia drugs for kidney disease.

        Can ANYONE tell me what any other tiny biotech woudl do if they had the research from these researchers in Japan on TB 4 and anemia in HUMAN samples???

        You are a horrible person Finklestein. Just horrible. A first grader could get this stuff out there better than you. Just like the other 480 abstracts on pub med. pitiful.

0.43+0.01(+1.56%)Aug 28 3:57 PMEDT